Cerus Appoints North American Sales Team Leadership

  Cerus Appoints North American Sales Team Leadership

Business Wire

CONCORD, Calif. -- December 11, 2013

Cerus Corporation (NASDAQ: CERS) announcedtoday the appointments of Kenneth
Trader as vice president, sales, North America, and Scott Buker as senior
director, North American market development. Both will join the company in
January 2014. Mr. Trader will be responsible for sales operations in North
America, including planning for anticipated product launches as well as
establishing and building the sales team responsible for product adoption. Mr.
Buker will be responsible for key launch activities and for management of
national accounts in North America.

Mr. Trader comes to Cerus with twenty-five years of leadership experience in
sales and marketing management, having served most recently as vice president,
sales and payer relations at US Bioservices, a division of AmerisourceBergen
Specialty Group. Prior to this role, Mr. Trader served as vice president,
corporate business development at AmerisourceBergen Specialty Group. He has
also previously held the roles of vice president of sales and marketing,
hemophilia health services with Accredo Health Group, and director of national
sales with Baxter BioScience, a division of Baxter Healthcare Corporation.
Throughout his career, Mr. Trader has consistently demonstrated success in
numerous biologic product launches and in building out commercial
organizations. Mr. Trader has served on the National Hemophilia Foundation's
board of directors since 2010, and currently holds the position of vice chair.

“We are delighted to welcome Ken to the Cerus team at such an exciting time in
the company’s history,” said William ‘Obi’ Greenman, Cerus’ chief executive
officer and president. “As we continue working to advance the INTERCEPT Blood
System in both the U.S. and Canada, Ken will immediately play a significant
leadership role in our ongoing launch preparations for North America, given
his depth of industry knowledge and experience.”

Mr. Buker joins Cerus with over thirty years of sales and marketing experience
in the blood testing and processing industry. He most recently served as
executive director, strategic accounts, for Biomedical Services at the
American Red Cross. Prior to this role, Mr. Buker served as senior director,
corporate accounts, and director, national accounts, also at the Red Cross.
Before joining the American Red Cross, he held leadership roles in sales and
marketing at Whatman plc, Johnson & Johnson, E.I. DuPont de Nemours, and
Abbott Laboratories.

“Scott brings a wealth of experience to our North American sales leadership
team,” said Mr. Greenman. “His extensive understanding of the U.S. blood
banking industry and his past successes in establishing and managing national
hospital accounts will be key to our launch planning and execution efforts.”

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of
blood safety. In in vitro studies, the company’s INTERCEPT Blood System has
been demonstrated to inactivate a broad range of viruses, bacteria and
parasites that may be present in donated blood, including established threats
such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as influenza, malaria and dengue. Cerus currently
markets and sells the INTERCEPT Blood System for both platelets and plasma in
Europe, the Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. In the United States, Cerus is
seeking regulatory approval of the INTERCEPT Blood System for plasma and
platelets. The INTERCEPT red blood cell system is in clinical development. See
http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements
contained in this press release that are not statements of historical fact may
be deemed to be forward-looking statements, including, without limitation,
statements relating to the potential regulatory approval and commercial launch
of the INTERCEPT Blood System inthe United States and other North American
countries, including the timing thereof, and customer adoption of the
INTERCEPT Blood System in the United States and other North American
countries. These forward-looking statements are based upon Cerus’ current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including, without
limitation, the risk thatCerusmay encounter unanticipated difficulties
complying with the prescribed submission timing or other modular Premarket
Approval application requirements of FDA, or complying with other regulatory
requirements for product approval in the U.S. or other North American
countries and the risk that customers may not adopt the INTERCEPT Blood System
in the U.S. or other North American countries, as well as other risks detailed
in Cerus'filings with theSecurities and Exchange Commission(SEC), including
inCerus'quarterly report on Form 10-Q for the quarter endedSeptember 30,
2013, filed with theSEConNovember 1, 2013. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release.Cerusdoes not undertake any obligation to update
any forward-looking statements as a result of new information, future events,
changed assumptions or otherwise.

Contact:

Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations
 
Press spacebar to pause and continue. Press esc to stop.